MONMOUTH JUNCTION, N.J.,
Aug. 2, 2016 /PRNewswire/
-- CytoSorbents Corporation (CTSO), a critical care
immunotherapy leader commercializing its CytoSorb® blood
purification filter to treat deadly inflammation in critically-ill
and cardiac surgery patients around the world, will report Q2 2016
financial results after the market close on Tuesday, August 9, 2016.
CytoSorbents' management will host a live conference call and
presentation webcast that will recount both operational and
financial progress during Q2 2016 followed by a question and answer
session.
Conference Call Details:
Date: Tuesday,
August 9, 2016
Time: 4:45 PM Eastern
Participant Dial-In: 1-719-457-2714
Live Presentation Webcast:
http://public.viavid.com/index.php?id=120613
It is recommended that participants dial in approximately 10
minutes prior to the start of the call. There will also be a
simultaneous live webcast of the conference call that can be
accessed through the following audio feed link:
http://public.viavid.com/index.php?id=120613
An archived recording of the conference call will be available
under the Investor Relations section of the Company's website at
http://www.cytosorbents.com/invest.htm
About CytoSorbents Corporation
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb is approved in the European Union with
distribution in 37 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents is
currently conducting its REFRESH (REduction in FREe Hemoglobin) 1
trial - a multi-center, randomized controlled study evaluating the
safety of intra-operative CytoSorb use in a heart-lung machine
during complex cardiac surgery. In early 2017, the company
plans to initiate a pivotal REFRESH 2 trial intended to support
U.S. FDA approval. CytoSorb has been used safely in more than
12,000 human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. The Company has numerous products under
development based upon this unique blood purification technology,
protected by 32 issued U.S. patents and multiple applications
pending, including HemoDefend™, ContrastSorb, DrugSorb and others.
Additional information is available for download on the Company's
websites: http://www.cytosorbents.com and
http://www.cytosorb.com
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2016, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and
Twitter
CytoSorbents
Contact: Amy Vogel
Investor
Relations
(732) 329-8885 ext.
*825
avogel@cytosorbents.com
|
Public Relations
Contact:
Amy
Phillips
Pascale
Communications
412-327-9499
amy@pascalecommunications.com
|
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-to-report-q2-2016-operating-and-financial-results-300307514.html
SOURCE CytoSorbents Corporation